Amplia's Narmafotinib Shows Enhanced Efficacy with kRAS Inhibitors in Preclinical Models
Event summary
- Amplia Therapeutics presented preclinical data at the AACR conference on March 6, 2026, showing narmafotinib enhances the activity of kRAS inhibitors in pancreatic, lung, and ovarian cancer models.
- The data indicates narmafotinib blocks resistance pathways, improving efficacy and durability of response when combined with kRAS inhibitors.
- Over 50 kRAS inhibitors are currently in clinical studies globally, with significant side effects and treatment-emergent resistance being common challenges.
- Amplia's narmafotinib is currently in clinical trials for advanced pancreatic cancer, with the ACCENT trial achieving a 35% confirmed response rate.
The big picture
The development of kRAS inhibitors is a highly competitive and active area in oncology, with over 50 different inhibitors in clinical studies. Amplia's narmafotinib, a best-in-class FAK inhibitor, has shown promising preclinical data in enhancing the efficacy of kRAS inhibitors by blocking resistance pathways. This strategic positioning could make Amplia a key player in the combination therapy space for solid tumors, particularly in pancreatic, lung, and ovarian cancers.
What we're watching
- Combination Therapy Potential
- How Amplia's narmafotinib will perform in combination with kRAS inhibitors in clinical settings, given its preclinical success in blocking resistance pathways.
- Regulatory Approval
- The pace at which Amplia can advance narmafotinib through clinical trials and secure regulatory approvals for combination therapies.
- Partnership Opportunities
- Whether Amplia can secure strategic partnerships with pharma and biotech companies actively developing kRAS inhibitors to accelerate clinical development.
Related topics